The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Kristen Kluska - Cantor - Analyst
: Hi, good morning, everybody. Congrats on these new great data you shared with us. Really appreciate it. So questions that I have are related to
the new data today. So I wanted to ask what the biggest criteria were in the trial that made the physicians comfortable to reduce and lower the
G-CSF usage? And while I recognize it wasn't a formal endpoint measured, I'm curious if the doctors had any anecdotes to share about any early
signals of reduced pain or better convenience benefits for patients.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 13, 2024 / 1:00PM, XFOR.OQ - Q3 2024 X4 Pharmaceuticals Inc Earnings Call
Question: Kristen Kluska - Cantor - Analyst
: Okay. Thanks. And then any early anecdotes or it's a little too early to make that assessment?
Question: Kristen Kluska - Cantor - Analyst
: Yes. And if I may ask one more question then. Can you talk a little bit more in terms of what lower G-CSF usage actually means? Is it that physicians
are assessing it every other day for usage? Is it the amount of G-CSF that's administered is lowered? And then do we have a general sense to give
us whether, what correlation of G-CSF usage could ultimately like truly lead to alleviating some of the dangerous side effects and the inconvenient
ones?
Question: Kristen Kluska - Cantor - Analyst
: Thanks again and congratulations.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 13, 2024 / 1:00PM, XFOR.OQ - Q3 2024 X4 Pharmaceuticals Inc Earnings Call
Question: Ted Tenzo - Piper Sandler - Analyst
: Okay. Thank you very much. Good morning everyone and congrats on the Phase 2 data. I had one quick follow-up question. When it comes to the
Phase 3 trial, and I'm wondering how, is there a way or are you looking at benefits, kind of following up on the last question from G-CSF reduction?
Is there any way to capture those in terms of improved tolerability, improved safety? And then I have a quick one on XOLREMDI.
Question: Ted Tenzo - Piper Sandler - Analyst
: Right. Okay. Yes, that makes a lot of sense. And also, I have to imagine it might take some time for some of those to emerge, but yes, that's great.
And then when it comes to XOLREMDI, you guys announced a new initiative. Can you just provide a little bit more detail around that in terms of
reaching out to the patients?
Question: Ted Tenzo - Piper Sandler - Analyst
: Yes. Thank you.
Question: Ted Tenzo - Piper Sandler - Analyst
: Yes, great. Excellent. Well, thank you very much. Appreciate the time.
Question: Steven Willey - Stifel - Analyst
: Yeah, good morning. Thanks for taking the questions. Maybe one on the data, one on XOLREMDI. So I guess on the data side, was there any
correlation between CN subtype and the rapidity and magnitude of G-CSF dose reduction? And then I guess, was there also any correlation between
the G-CSF dose these patients were receiving at baseline and then the magnitude of the dose reduction they were able to achieve?
Question: Steven Willey - Stifel - Analyst
: Okay. And then on XOLREMDI, I know you've hit 100% of your target accounts. I think you also mentioned 60% of HCPs have increased their
screening. But I guess, do you have a sense of how many of these HCPs that you're targeting are indeed actively screening? Just wondering, I guess,
how low of a base you're starting at here and what kind of runway you might have? Thanks.
Question: Steven Willey - Stifel - Analyst
: All right. Thanks for taking the questions.
Question: David Bautz - Zachs - Analyst
: Hey, good morning, everyone. For XOLREMDI, I'm curious if you will be able to provide any type of sales guidance numbers moving into 2025. And
then for the new Phase 2 data this morning, I realize the numbers are small, but was there any data collected on infections, number of infections
or types and then particularly for those patients where G-CSF was reduced?
Question: David Bautz - Zachs - Analyst
: Okay, great. Thanks for taking the questions.
| 
